Potential Pharmacokinetic Interaction of Human Immunodeficiency Virus (HIV) Antiretroviral Agents as Fixed-dose Combinations and Riociguat in HIV Patients
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Riociguat (Primary) ; Abacavir/dolutegravir/lamivudine; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Bayer
- 19 Oct 2016 Status changed from recruiting to completed.
- 11 Oct 2016 Planned End Date changed from 1 Apr 2017 to 1 Oct 2016.
- 11 Oct 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2016.